title: [Efficacy and safety of infliximab in patients with rheumatoid arthritis].
abstract: OBJECTIVE
  To investigate the efficacy and safety of Infliximab (IFX) plus methotrexate (MTX) combination therapy in patients with rheumatoid arthritis (RA).
  
  
  METHODS
  Prospectively observe refractory RA patients who were treated with combination therapy of MTX and IFX. IFX was infused at the dosage of 3 mg/kg, in week 0, 2, 6, and then every 8 weeks. During treatment, clinical variables, disease activity and adverse effects were evaluated.
  
  
  RESULTS
  After treatment, 69.8%, 52.4%, 29.5% and 7.2% RA patients achieved ACR20, ACR50, ACR70 and ACR90 respectively. There were significant statistical differences in the changes of swollen joint counts, tender joint counts, VAS scale, patient' s global assessment, and physician's global assessment before and after therapy.
  
  
  CONCLUSIONS
  Infliximab plus MTX achieved significant efficacy and safety in refractory RA patients.
authors: Department of Rheumatology and Immunology, Peking Union Medical College Hospital, Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing 100730, China. zhangsamfc@hotmail.com
authors: Wen
authors: W
authors: Zhang
authors: Qun
authors: Q
authors: Shi
authors: Dong-hai
authors: DH
authors: Wu
authors: Chun-de
authors: CD
authors: Bao
authors: Nan-ping
authors: NP
authors: Yang
authors: Zhan-guo
authors: ZG
authors: Li
authors: Ping
authors: P
authors: Zhu
authors: Xiao
authors: X
authors: Zhang
authors: Ci-bo
authors: CB
authors: Huang
authors: Dong-yi
authors: DY
authors: He
authors: Zhi-zhong
authors: ZZ
authors: Ye
authors: Yi
authors: Y
authors: Tao
authors: Yong-fei
authors: YF
authors: Fang
authors: Jie-ruo
authors: JR
authors: Gu
authors: Hua-xiang
authors: HX
authors: Wu
authors: Ling-yun
authors: LY
authors: Sun
authors: Xiu-yan
authors: XY
authors: Yang
authors: Feng
authors: F
authors: Huang
authors: Hu-ji
authors: HJ
authors: Xu
authors: Dong-bao
authors: DB
authors: Zhao
authors: Miao-jia
authors: MJ
authors: Zhang
authors: Yi
authors: Y
authors: Zheng
authors: Mai-xing
authors: MX
authors: Ai
authors: Jun
authors: J
authors: Lu
authors: Feng-chun
authors: FC
authors: Zhang
mesh_terms: D000328:Adult; D000368:Aged; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D018501:Antirheumatic Agents / Q000627:therapeutic use*; D001172:Arthritis, Rheumatoid / Q000188:drug therapy*; D005260:Female; D006801:Humans; D000069285:Infliximab; D008297:Male; D008727:Methotrexate / Q000627:therapeutic use; D008875:Middle Aged; D011446:Prospective Studies; D055815:Young Adult
chemical_list: D000911:Antibodies, Monoclonal; D018501:Antirheumatic Agents; D000069285:Infliximab; D008727:Methotrexate